Highlights Dr. Lal PathLabs Limited Bombay S.E.

Equities

LALPATHLAB

INE600L01024

Delayed Bombay S.E. Other stock markets 02:16:09 15/05/2024 pm IST			5-day change	1st Jan Change
2,485 ^INR	-0.23%		+6.67%	-3.46%

14/05	Nomura Upgrades Dr. Lal Pathlabs to Buy From Neutral, Adjusts Price Target to INR2,713 From INR2,505	MT
10/05	Transcript : Dr. Lal PathLabs Limited, Q4 2024 Earnings Call, May 10, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Dr. Lal Pathlabs' Fiscal Q4 Consolidated Net Profit Rises; Share Up 6%	13/05	MT
India's Dr. LalPath Labs posts higher Q4 profit rises on healthy testing demand	10/05	RE
Dr. Lal PathLabs Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024	10/05	CI
Dr. Lal PathLabs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	10/05	CI
Dr. Lal Pathlabs' Consolidated Profit Jumps in Fiscal Q3; EPS, Revenue Miss Estimates	02/02	MT
Dr. Lal PathLabs Seeks M&A	01/02	CI
India's Dr. Lal PathLabs posts 54% jump in Q3 profit on flu, COVID tests	01/02	RE
Dr. Lal PathLabs Limited Approves Second Interim Dividend for the Fiscal Year 2023-24	01/02	CI
Dr. Lal PathLabs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	01/02	CI
Dr. Lal Pathlabs Board to Consider Second Interim Dividend for Fiscal 2024	25/01	MT
Dr Lal Pathlabs' Consolidated Profit Jumps in Fiscal Q2; Shares Climb 5%	03/11	MT
Dr. Lal PathLabs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	02/11	CI
Dr. Lal Pathlabs Limited Approves to Declare Final Dividend for the Financial Year Ended March 31, 2023	12/23/12	CI
Dr Lal Pathlabs' Consolidated Profit Jumps in Fiscal Q1; Revenue Meets Estimates	31/23/31	MT
Dr. Lal PathLabs Seeks Inorganic Opportunity	27/23/27	CI
Dr. Lal Pathlabs Limited Proposes Interim Dividend for the Financial Year 2023-24	27/23/27	CI
Dr. Lal PathLabs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	27/23/27	CI
Dr. Lal PathLabs Limited acquired additional 10% stake in Aprl Pathlabs Private Limited.	27/23/27	CI
Dr. Lal PathLabs' Consolidated Net Profit Declines in Fiscal Q4; Shares Up 3%	12/23/12	MT
Dr. Lal Pathlabs' Consolidated Profit Drops in Fiscal Q4	11/23/11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Dr. Lal PathLabs Limited Bombay S.E.

Equities

LALPATHLAB

INE600L01024

Highlights

Filters